Contract pharmaceutical research firm expands to New Jersey
Concentrics grows in spite of recession as drug companies look for help to handle patent expirations
Pharmaceutical
Articles
Lilly’s Lechleiter: No change in plans
The global financial press keeps asking John Lechleiter for his end-game strategy to survive Eli Lilly and Co.'s nightmarish
patent challenges. And, like a broken record, the Lilly CEO keeps giving the same answer: pipeline, pipeline, pipeline—no
mega-merger.
Men on Viagra, Cialis show triple rate of sex diseases in study
The findings suggest that users of drugs to treat erectile dysfunction, including Eli Lilly’s Cialis, may be more likely to
engage in unsafe sex than nonusers.
Lilly acquires biotech company with pancreatic drug
Massachusetts-based Alnara Pharmaceuticals Inc., which has attracted $55 million in venture capital in the past two years,
recently submitted its drug to the FDA for market approval.
Grassley asks Lilly, peers about whistleblower treatment
U.S. Senator Charles Grassley asked 16 drugmakers, including Eli Lilly & Co., Pfizer Inc. and AstraZeneca Plc, to reveal
how they treat whistleblowers who file complaints under the False Claims Act.
Marcadia enlists Lilly to help develop new diabetes drug
The two companies will jointly develop a short-acting glucagon drug, which they hope proves more convenient than Lilly’s
current Glucagon for patients with severe hypoglycemia.
Lilly, Amylin stock rises on drug postponement
Roche Holding AG’s decision to postpone its experimental diabetes drug is helping boost shares in Amylin Pharmaceuticals
Inc. and drug partner Eli Lilly and Co.
Arcadia sees smaller quarterly, fiscal-year losses
Despite losses, company sees growth in its DailyMed pharmacy services, which packages the right dosages of prescriptions to
make it easier for patients to follow their regimens.
Research reforms will force Lilly, others to test how drugs stack up
The federal government is currently doling out $1.1 billion in stimulus funds to pay for research that compares multiple medical
treatments against one another to determine which is most effective. Drug companies like Eli Lilly and Co. are wary that comparative-effectiveness
research could threaten their sales.
Erbitux fails to stop colon cancer before it spreads
Eli Lilly and Co. and Merck KGaA drug failed to slow tumors in a study designed to expand the medicine’s use to patients whose
disease is in an earlier stage.
Genetic testing could spur Erbitux drug sales
The drugmakers are counting on screening for the so-called K-ras gene to spur use of Erbitux in metastatic colorectal cancer.
Lilly grows Alimta’s sales by shrinking market
In 2008, Eli Lilly and Co. asked drug regulators to change the label on Alimta so Lilly could no longer promote it as a treatment
for all patients suffering from non-small-cell lung cancer, but for only about 70 percent of the patients. Since then, sales
of the drug have accelerated, growing a whopping 48 percent last year.
Cancer researcher battling Semafore in court
Former collaborator alleges firm breached its agreement with him and refused to pay royalty income.
Biopharma fueling boom in refrigerated warehousing
In the past few years, a handful of cold storage facilities have sprouted locally by playing to Indianapolis' strengths
in warehousing and life sciences.
Effective stats are new hurdle for U.S. drugmakers
WellPoint Inc.'s announcement of comparative effectiveness research guidelines last week marks a new era for U.S. drugmakers.
The Indianapolis-based health insurer will use studies that compare the effectiveness of one drug against another as a complement
to typical clinical trial research that compares a drug against a placebo sugar pill.
Moody’s lowers Eli Lilly outlook to ‘negative’
Moody's Investors Service on Friday lowered its rating outlook on drugmaker Eli Lilly and Co. to "negative"
from "table" due in part to the looming expiration of patents protecting key drugs from generic competition.
Drug-spending increase highest in four years
The price increase was fueled by the debate over the health-care overhaul in Washington, D.C., Medco Health Solutions Inc. CEO David Snow said.
Latest Lilly job cuts target marketing employees
Indianapolis-based drugmaker Eli Lilly and Co. is on course to cut 5,500 jobs by the end of 2011 in a bid to eliminate $1
billion in annual expenses.
Lilly hopes Elanco unit becomes a cash cow
Elanco Animal Health chief Jeff Simmons predicts that consumers will opt for food made cheaper by using
Elanco’s productivity-enhancing drugs over pricier organic and locally grown products. But, as a hedge,
he has Elanco developing products to help organic farmers, too.
Lilly sues to block copy of Evista osteoporosis drug
Watson Pharmaceuticals filed for FDA approval to sell a low-cost version of Eli Lilly and Co.’s osteoporosis medicine. Indianapolis-based
Lilly is seeking a court order that would block approval until three of its patents expire in 2017.